Two major options used in the treatment of DCM are oral drugs and implantable devices. Oral drugs available are beta blockers, diuretics, digitalis, angiotensin II receptor blocker (ARBs), warfarin and angiotensin-converting enzyme inhibitors (ACE inhibitors). In implantable devices, heart pumps and cardioverter-defibrillators are mainly used.
The growth in DCM treatment market is due to prominent rise in number of heart failure patients worldwide over the years, R&D activities and increased awareness for timely diagnosis.
This report provides information on DCM treatment market size for the year 2014-2016, and forecast of the same for year 2021. It also focuses on market drivers, challenges, restraints, market dynamics, growth indicators, competitive landscape, potential growth opportunities and other key aspects with respect to DCM.
Geographic regions analyzed for this market is divided into four regions i.e. North America, Europe, Asia Pacific and Rest of the World. Due to increase in numbers of heart problems over the years North America and Asia-Pacific are expected to be major markets for DCM. Europe and Row are other prominent markets for the disease.
This report identifies global DCM on the basis of treatment type and regional market as follows:
Dilated Cardiomyopathy treatment market is segmented based on available treatment options. Mainly two treatment options, drugs and implantable devices are in the market
This report is further segmented based on potential markets for DCM. A detailed analysis by region – United States, Europe, Asia-Pacific (APAC) and Rest of the World (RoW), has been provided in this report.
This report looks into all the major companies operating in the DCM treatment. Some of the major companies’ profiles are as follows:
Janssen Pharmaceuticals Inc.
Merck & Co. Inc.
Novartis International AG
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Dilated Cardiomyopathy Treatment - Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Dilated Cardiomyopathy Treatment - Market Forces
4.1.1. Rise in number of heart failure patients
4.5. Porter’s Five Force Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Customers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Dilated Cardiomyopathy Treatment Market – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Dilated Cardiomyopathy Treatment Market
6.1. By type of treatment - Drugs
6.1.1. Beta blockers
6.1.4. Angiotensin II receptor blocker (ARBs)
6.1.5. Angiotensin-converting enzyme inhibitors (ACE inhibitors)
6.2. By type of treatment – Implantable devices
6.2.1. Heart pumps
6.2.2. Cardioverter-defibrillators (ICDs)
6.2.3. Biventricular pacemakers
7. Dilated Cardiomyopathy Treatment Market, By Geography
7.3.6. Rest of Europe
7.4. Asia Pacific
7.4.2. South Korea
7.4.5. Rest of Asia Pacific
8. Market Entropy
8.2. Technological Developments
8.3. Merger & Acquisitions, and Joint Ventures
8.4. Supply - Contract
9. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
9.2. Pfizer Inc.
9.3. Novartis A.G
9.4. Merck and Co.
9.5. Janssen Pharmaceuticals
9.6. AstraZeneca plc.
9.7. Array BioPharma, Inc
9.8. Vericel Corporation
9.9. Celladon Corporation
9.10. Teva Pharmaceutical Industries Ltd.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10.3. Research Methodology
10.4. Expert Insights